Authors: WORTH LL JAFFE N BENJAMIN RS PAPADOPOULOS NE PATEL S RAYMOND AK JIA SF RODRIGUEZ C GANO J GIANAN MA KLEINERMAN ES

Citation: Ll. Worth et al., PHASE-II STUDY OF RECOMBINANT INTERLEUKIN-1-ALPHA AND ETOPOSIDE IN PATIENTS WITH RELAPSED OSTEOSARCOMA, Clinical cancer research, 3(10), 1997, pp. 1721-1729

Authors: MURRAY JL KLEINERMAN ES JIA SF ROSENBLUM MG ETON O BUZAID A LEGHA S ROSS MI THOMPSON L MUJOO K RIEGER PT SALEH M KHAZAELI MB VADHANRAJ S

Citation: Jl. Murray et al., PHASE-IA IB TRIAL OF ANTI-GD2 CHIMERIC MONOCLONAL-ANTIBODY-14.18 (CH14.18) AND RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (RHGM-CSF) IN METASTATIC MELANOMA/, Journal of immunotherapy with emphasis on tumor immunology, 19(3), 1996, pp. 206-217

Authors: ASANO T AN T JIA SF KLEINERMAN ES

Citation: T. Asano et al., ALTERED MONOCYTE CHEMOTACTIC AND ACTIVATING FACTOR GENE-EXPRESSION INHUMAN GLIOBLASTOMA CELL-LINES INCREASED THEIR SUSCEPTIBILITY TO CYTOTOXICITY, Journal of leukocyte biology, 59(6), 1996, pp. 916-924

Authors: KLEINERMAN ES MEYERS PA RAYMOND AK GANO JB JIA SF JAFFE N

Citation: Es. Kleinerman et al., COMBINATION THERAPY WITH IFOSFAMIDE AND LIPOSOME-ENCAPSULATED MURAMYLTRIPEPTIDE - TOLERABILITY, TOXICITY, AND IMMUNE STIMULATION, Journal of immunotherapy with emphasis on tumor immunology, 17(3), 1995, pp. 181-193